GSK-201749

Study Sponsor: GSK

Study Title

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)

Medicine or Vaccine (generic name)

umeclidinium bromide/vilanterol

Sponsor Identification Number

201749

Trial Registry Identification Number(#'s)

NCT03034915 2016-002513-22

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 4

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=201749

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03034915

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002513-22

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

There is a Publication Steering Committee for this study. This study is available in CDISC format.

Date Added to this Site

January 2020